earnings_release-073112.htm

CONTACT:

Jeff Macdonald

Acorda Therapeutics

(914) 326-5232

jmacdonald@acorda.com

FOR IMMEDIATE RELEASE

Acorda Therapeutics Reports Second Quarter 2012 Financial Results

·	AMPYRA® (dalfampridine) Second Quarter Net Revenue of $66.3 Million

·	Combined Second Quarter ZANAFLEX Franchise and ex-U.S. FAMPYRA® Royalty Revenue of $7.1 Million

ARDSLEY, N.Y. – JULY 31, 2012 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the second quarter ended June 30, 2012.

“Acorda made impressive progress across a range of its programs in the second quarter. AMPYRA net sales increased 15.5% compared to the first quarter, and 28% compared to the second quarter of 2011. We are encouraged by the positive physician and consumer response to the promotional initiatives we launched earlier in the year, which have contributed to this growth,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “In addition, we initiated a Phase 2 clinical trial of AMPYRA in people with post-stroke deficits and completed recruitment for the first stage of our proof-of-concept clinical trial of AMPYRA in people with cerebral palsy.”

FINANCIAL RESULTS

The Company reported GAAP net income of $4.5 million for the quarter ended June 30, 2012, or $0.11 per diluted EPS, including share-based compensation charges totaling $5.6 million. The GAAP net loss for the second quarter of 2011 was $0.3 million, or $0.01 per diluted EPS including share-based compensation charges of $5.0 million.

Non-GAAP net income, before share-based compensation charges, for the quarter ended June 30, 2012 was $10.8 million, or $0.27 per diluted EPS, compared to a non-GAAP net income of $7.8 million, or $0.19 per diluted EPS for the same quarter in 2011.

AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg net revenue - For the quarter ended June 30, 2012, the Company reported AMPYRA net revenue of $66.3 million, compared to $51.8 million in net revenue for the same quarter in 2011. AMPYRA revenue is recognized following shipment of the product from the Company’s distribution facility to its network of specialty pharmacies.

The Company is reiterating 2012 AMPYRA net sales guidance of $255-$275 million.

ZANAFLEX CAPSULES® (tizanidine hydrochloride), ZANAFLEX® (tizanidine hydrochloride) tablets and authorized generic tablets net revenue and royalties - For the quarter ended June 30, 2012, the Company reported combined net revenue from ZANAFLEX CAPSULES and ZANAFLEX tablets sales of $2.5 million. Revenue from the sale of authorized generic tizanidine hydrochloride capsules to Watson totaled $0.3 million and royalties from Watson for the sale of authorized generic tizanidine hydrochloride capsules were $1.8 million. Combined net revenue from ZANAFLEX CAPSULES and ZANAFLEX tablets sales were $11.1 million for the same quarter in 2011.

ZANAFLEX revenue is recognized using a deferred revenue recognition model, meaning ZANAFLEX CAPSULES and ZANAFLEX tablets shipments to wholesalers are recorded as deferred revenue and only recognized as revenue when end-user prescriptions of ZANAFLEX CAPSULES and ZANAFLEX tablets are reported. Authorized generic product sold to Watson is recorded as sales when shipped.

ZANAFLEX CAPSULES and ZANAFLEX tablets shipments - Total ZANAFLEX CAPSULES and ZANAFLEX tablets shipments for the quarter ended June 30, 2012 were $2.7 million, compared to total shipments of $14.2 million for the same quarter in 2011. The decrease is due to the launch of generic versions of ZANAFLEX CAPSULES during the first quarter of 2012.

FAMPYRA® (prolonged-release fampridine tablets) royalties - For the quarter ended June 30, 2012, the Company reported FAMPYRA royalties from sales outside of the U.S. of $2.5 million, compared to $0.1 million for the same quarter in 2011.

The Company continues to expect combined ZANAFLEX franchise (including revenues from authorized generic capsules) and ex-U.S. FAMPYRA royalty revenue of at least $25 million.

Cost of sales for the quarter ended June 30, 2012 were $13.6 million, compared to $12.0 million for the same quarter in 2011. Included in cost of sales for the quarter ended June 30, 2012 was $0.3 million in cost of authorized generic tizanidine hydrochloride capsules sold to Watson.

Research and development (R&D) expenses for the quarter ended June 30, 2012 were $12.6 million, including $1.3 million of share-based compensation, compared to $12.0 million including $1.5 million of share-based compensation for the same quarter in 2011. R&D expenses for the quarter ended June 30, 2012 included costs related to the Neuronex agreement, AMPYRA post-marketing studies and life cycle management programs, and the development of the Company’s pipeline products, including clinical trial expenses for Glial Growth Factor 2 (GGF2) and AMPYRA proof-of-concept cerebral palsy and post-stroke deficits studies.

The Company continues to expect R&D expenses for the full year 2012 to be $50-$60 million, excluding share-based compensation.

Sales, general and administrative (SG&A) expenses for the quarter ended June 30, 2012 were $44.2 million, including $4.3 million of share-based compensation, compared to $40.1 million including $3.5 million of share-based compensation for the same quarter in 2011.

The Company continues to expect SG&A expenses for the full year 2012 to be $145-$160 million, excluding share-based compensation charges.

For the quarter ended June 30, 2012, the Company closed in a strong financial position with cash, cash equivalents and short-term and long-term investments of $303.0 million, up from $295.3 million in the first quarter.

AMPYRA UPDATE

·	A post-approval commitment study examining the use of a 5mg dose of AMPYRA has completed enrollment. The Company expects to announce results of the study in August.

·	In June, the Company received an untitled letter from FDA instructing the Company to discontinue use of certain promotional material. The Company has complied with the FDA request.

In May, the Company presented research at the 4th Collaborative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) that examined the impact of walking impairment on different aspects of the lives of people with MS, as well as the use of AMPYRA in the United States.

PIPELINE UPDATE

Page 2 of 8

·	The proof-of-concept clinical study of AMPYRA in patients with post-stroke deficits was initiated in the second quarter. The Company expects to announce initial results in early 2013.

·	The proof-of-concept clinical study of AMPYRA in adults with cerebral palsy is ongoing. Recruitment for the single-dose phase of the trial has been completed, and the Company expects to announce initial results for this stage by the end of the year.

CORPORATE UPDATES

·	The Company was recognized with an American Business Awards “Stevie” as Best Company of the Year in the pharmaceutical category.

·	Medical Marketing & Media has named AMPYRA.com as a finalist for the “Best Branded Website” of 2012.

In May, the Company received a Warning Letter from the U.S. Food and Drug Administration (FDA) regarding the timeliness of adverse event (AE) reporting and AE record-keeping procedures. The Company has taken actions to improve internal processes and ensure compliance with AE reporting regulations, and is providing regular updates to the FDA.

This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain historical and forward-looking non-GAAP financial measures. In particular, Acorda has provided income (loss), adjusted to exclude share-based compensation charges and the payments associated with Neuronex in 2012 and the AC105 license fee in 2011. Also, Acorda has provided projected amounts of research and development (R&D) and sales, general, and administrative (SG&A) expenses excluding share-based compensation charges. These non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, we believe the presentation of these non-GAAP financial measures when viewed in conjunction with our GAAP results, provide investors with a more meaningful understanding of our ongoing and projected operating performance because they exclude non-cash charges that are substantially dependent on changes in the market price of our common stock and expenses and income that do not arise from the ordinary course of our business. We believe these non-GAAP financial measures help indicate underlying trends in the company’s business and are important in comparing current results with prior period results and understanding projected operating performance. Also, management uses these non-GAAP financial measures to establish budgets and operational goals, and to manage the company’s business and to evaluate its performance. A reconciliation of the historical non-GAAP financial results presented in this release to our GAAP financial results is included in the attached financial statements.

WEBCAST AND CONFERENCE CALL

Ron Cohen, President and Chief Executive Officer, and David Lawrence, Chief Financial Officer, will host a conference call today at 8:30 a.m. ET to review the Company’s second quarter 2012 results.

To participate in the conference call, please dial 866-804-6928 (domestic) or 857-350-1674 (international) and reference the access code 49836380. The presentation will be available via a live webcast on the Investor section of www.acorda.com.

A replay of the call will be available from 10:30 a.m. ET on July 31, 2012 until midnight on August 31, 2012. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 63308993. The archived webcast will be available for 30 days in the Investor Relations section of the Acorda website at www.acorda.com.

Important Safety Information

AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses. AMPYRA is contraindicated in patients with a prior history of seizure. Discontinue AMPYRA use if seizure occurs.

AMPYRA is contraindicated in patients with moderate or severe renal impairment (CrCl less-than or equal to 50 mL/min); the risk of seizures in patients with mild renal impairment (CrCl 51-80 mL/min) is unknown, but AMPYRA plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a

Page 3 of 8

dose that may be associated with an increased risk of seizures; estimated CrCl should be known before initiating treatment with AMPYRA.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

Urinary tract infections were reported more frequently as adverse reactions in patients receiving AMPYRA 10 mg twice daily compared to placebo.

The most common adverse events (incidence greater-than or equal to 2% and at a rate greater than the placebo rate) for AMPYRA in MS patients were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain.

For full U.S. Prescribing Information and Medication Guide for AMPYRA, please visit: www.AMPYRA.com.

About AMPYRA (dalfampridine)

AMPYRA is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA, which was previously referred to as Fampridine-SR, is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP), and is known as prolonged-, modified, or sustained-release fampridine (FAMPYRA®) in some countries outside the United States (U.S).

In laboratory studies, dalfampridine extended release tablets has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged. AMPYRA is being developed and commercialized in the U.S. by Acorda Therapeutics; FAMPYRA is being developed and commercialized by Biogen Idec in markets outside the U.S. based on a licensing agreement with Acorda. AMPYRA and FAMPRYA are manufactured globally by Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, based on a supply agreement with Acorda.

AMPYRA is available by prescription in the United States. For more information about AMPYRA, including patient assistance and co-pay programs, healthcare professionals and people with MS can contact AMPYRA Patient Support Services at 888-881-1918.

AMPYRA Patient Support Services is available Monday through Friday, from 8:00 a.m. to 8:00 p.m. Eastern Time at 888-881-1918. For full U.S. Prescribing Information and Medication Guide, please visit: www.AMPYRA.com.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.

Acorda markets AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland Limited.

The Company also markets ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity. Acorda also receives sales royalties on tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES distributed by Watson Pharmaceutics, Inc. under its agreement with Acorda.

Acorda is developing an industry-leading pipeline of novel neurological therapies. The Company is studying AMPYRA to improve a range of functional impairments caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, Acorda is developing

Page 4 of 8

clinical stage compounds AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and spinal cord injury. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in spinal cord injury.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including any acquired or in-licensed programs; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen Idec in connection therewith; competition, including the impact of generic competition on Zanaflex Capsules revenues; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and the ability to obtain additional financing to support our operations. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Page 5 of 8

Financial Statements

Acorda Therapeutics, Inc.

Condensed Consolidated Balance Sheet Data

(in thousands)

(Unaudited)

	June 30,		December 31,
	2012		2011
Assets
Cash, cash equivalents and short-term investments	$	255,850	$	295,907
Trade receivable, net		23,607		22,828
Other current assets		18,367		13,825
Finished goods inventory		29,413		28,382
Long-term investments		47,118		-
Property and equipment, net		14,290		3,858
Intangible assets, net		8,755		8,769
Other assets		5,653		5,919
Total assets	$	403,053	$	379,488

Liabilities and stockholders' equity
Accounts payable, accrued expenses and other liabilities	$	47,926	$	45,542
Deferred product revenue		28,991		30,599
Current portion of deferred license revenue		9,057		9,057
Current portion of notes payable		1,144		1,144
Current portion of revenue interest liability		1,315		1,001
Long-term liabilities		9,708		6,266
Non-current portion of revenue interest liability		2,048		2,928
Non-current portion of deferred license revenue		73,214		77,742
Stockholders' equity		229,650		205,209
Total liabilities and stockholders' equity	$	403,053	$	379,488

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2012			2011			2012			2011
Revenues:
Net product revenues	$	69,112		$	62,878		$	134,785		$	121,803
License revenue		2,264			2,264			4,529			4,529
Royalty revenues		4,280			134			7,590			230
Total revenues		75,656			65,276			146,904			126,562

Costs and expenses:
Cost of sales		13,576			12,048			26,040			24,098
Cost of license revenue		158			159			317			317
Research and development		12,634			12,008			23,659			22,716
Selling, general and administrative		44,230			40,141			82,975			78,070
Total operating expenses		70,598			64,356			132,991			125,201

Operating income	$	5,058		$	920		$	13,913		$	1,361

Other expense, net		(233	)		(1,143	)		(870	)		(2,139	)
Income (loss) before income taxes		4,825			(223	)		13,043			(778	)
Provision for income taxes		(280	)		(62	)		(652	)		(179	)

Net income (loss)	$	4,545		$	(285	)	$	12,391		$	(957	)

Net income (loss) per common share - basic	$	0.12		$	(0.01	)	$	0.31		$	(0.02	)
Net income (loss) per common share - diluted	$	0.11		$	(0.01	)	$	0.31		$	(0.02	)
Weighted average per common share - basic		39,433			38,937			39,387			38,859
Weighted average per common share - diluted		40,099			38,937			40,253			38,859

	Three Months Ended					Six Months Ended
	June 30,					June 30,
	2012		2011			2012		2011

GAAP net income (loss)	$	4,545	$	(285	)	$	12,391	$	(957	)
Pro forma adjustments:
Neuronex payments included in R&D (Note 1)		700		-			3,200		-

License agreement expense in R&D (Note 2)		-		3,000			-		3,000

Share-based compensation expenses included in R&D		1,339		1,487			2,328		2,590
Share-based compensation expenses included in SG&A		4,254		3,549			7,456		6,201
Total share-based compensation expenses		5,593		5,036			9,784		8,791

Total pro forma adjustments		6,293		8,036			12,984		11,791

Non-GAAP net income	$	10,838	$	7,751		$	25,375	$	10,834

Net income per common share - basic	$	0.27	$	0.20		$	0.64	$	0.28
Net income per common share - diluted	$	0.27	$	0.19		$	0.63	$	0.27
Weighted average per common share - basic		39,433		38,937			39,387		38,859
Weighted average per common share - diluted		40,099		40,158			40,253		39,964

Note 1: $2.0 million upfront payment and $1.2 million in R&D payments per agreement with Neuronex.
Note 2: $3.0 million upfront expense related to licensed worldwide development and commercialization rights to a proprietary magnesium formulation from Medtronic, Inc. (AC105).